AI Titans, Fed Doubts and a +$70 Billion Hollywood Plot Twist: This Week in Markets - Dec. 5, 2025 -( $DV $EPRX $INTG $META $MODD $MTWO $NVDA $OKLO $ORCL $PLTR $TSLA $TSM $WBD Rise!) - Vista Partners LLC

U.S. stocks tiptoed higher into the week ending Friday, Dec. 5, 2025, with investors behaving less like adrenaline junkies and more like cautious connoisseurs, nudging major indexes toward record territory while pretending not to look too excited. The S&P 500 added roughly 0.3% for the week, finishing just a whisker below its all‑time closing high, while the Dow advanced about 0.5%, the Nasdaq climbed close to 0.9%, and the small‑cap Russell 2000 saw a gain of .84%.

Indexes and macro tone

The S&P 500 and Dow hovered near record levels, supported by resilient large‑cap earnings and a market increasingly convinced that the Federal Reserve is cutting rates next week, even if it is not yet ready to shower Wall Street with multiple rate cuts. The Nasdaq’s nearly 1% weekly rise reflected continued enthusiasm for AI and tech bellwethers.

Macroeconomic data for the week leaned mildly favorable for risk assets, with cooling inflation in Fed‑watched gauges helping to anchor expectations that the next significant policy move is more likely to be a cut than a hike. Markets spent much of the week calibrating the odds of 2026 rate cuts ahead of the upcoming Federal Open Market Committee gathering, treating every inflation and activity print less as fresh information and more as a confirmation that the “higher for longer” story is quietly aging out of the narrative.

Rates, yields, Fed and Washington

Treasury yields moved higher over the week, with the 10‑year posting its biggest weekly jump since the spring as investors trimmed aggressive easing bets, steepening parts of the curve but leaving it still notably inverted by historical standards. Futures pricing now points to a shallower and later rate‑cut path, suggesting the Fed can afford to wait for clearer evidence that growth and inflation are decisively cooling before it cuts, even as markets eye the next FOMC meeting as the stage for updated guidance rather than a policy shock.

In Washington, investors remained attuned to ongoing fiscal debates and the risk of another government‑funding showdown, but shutdown fears stayed largely in the background, more a risk‑management footnote than a dominant market driver this week. Trade‑policy chatter, including tariff and industrial‑policy updates, continued to simmer, yet no single tariff headline meaningfully altered the week’s risk tone, leaving the macro spotlight firmly on inflation, growth data and the coming Fed communications.

Commodities and crypto

Gold extended what has become a historic 2025 rally, closing at $4,226.90 as momentum traders and geopolitically cautious investors found common cause in the yellow metal near record levels. Silver followed with its characteristic higher‑beta flair casing at $58.79, +2.26%, benefitting from both precious‑metal flows and hopes for a firmer industrial cycle.

Oil prices saw choppy trading as markets weighed supply discipline against concerns over global demand, leaving crude stuck in a range that reflects neither crisis nor comfort and closed at $60.16/bbl up 1.42% over the last 5-days. Bitcoin, meanwhile, continued to demonstrate an increasingly loose correlation with equities, trading higher on the week by +3.38% to just under $90k and reminding traditional asset allocators that risk appetite now has a digital expression that does not always wait for the S&P’s permission.

Big tech, pharma and chip leaders

Eli Lilly (LLY, $1,010.31, -6.06% over the last 5-days) but remained firmly in the market’s pantheon, having recently joined the trillion‑dollar‑valuation club and continuing to ride expectations for obesity and oncology franchises that have turned a once‑steady pharma name into a growth stock in blue‑chip clothing. Nvidia (NVDA, $182.41, +3.06% over the last 5-days), a central character in the AI saga, saw sentiment constrained by worries over sustainability and valuation even after strong fundamental performance, underscoring how far expectations have run ahead of even eye‑popping earnings.

Apple (AAPL, $278.78. -.03% over the last 5-days) and other mega‑cap tech names were frequent subjects of upbeat analyst commentary during the week, with calls emphasizing their roles as core beneficiaries of AI, services growth and ecosystem stickiness, providing ballast to the major indexes. Taiwan Semiconductor Manufacturing (TSM, $294.72, +.37% over the last 5-days), the indispensable foundry behind much of the AI and smartphone boom, remained a structural winner in consensus narratives, as investors continued to view its advanced‑node capacity as critical infrastructure for the entire tech complex.

AI, software and data names

Palantir’s (PLTR, $181.76, +7.90% over the last 5-days) strong year‑to‑date performance — with shares having more than doubled in 2025 — kept the stock in the conversation as one of the AI beneficiaries that managed to convert narrative into price appreciation, even as some higher‑profile peers wrestled with volatility. Oracle (ORCL, $217.58, +7.74% over the last 5-days) drew supportive analyst coverage that reiterated positive views on its long‑term AI and cloud positioning despite near‑term concerns about capex intensity and debt, helping to stabilize sentiment around the name.

Meta ($673.42, +3.93% over the last 5-days) maintained its status as one of the large‑cap platforms benefiting from efficiency efforts and an improving digital‑ad environment, while Intel remained central to debates over whether legacy chipmakers can re‑establish leadership in a world dominated by AI‑optimized designs. They also announced a pullback on spend in their metaverse business and acquired AI-wearables startup Limitless. Broadcom (AVGO, $390.24, -3.16% over the last 5-days), but remains backed by bullish analyst assessments tied to AI‑related demand, continued to be framed as a key infrastructure enabler for accelerators and data‑center networking.

Autos, industrials, consumer and materials

Tesla (TSLA, $455, +5.77% over the last 5-days) remained emblematic of the market’s appetite for volatility, tethered to broader EV and AI narratives as investors weighed cyclical pressures in autos against the company’s software and autonomy ambitions. McDonald’s (MCD, $311.23, -.19% over the last 5-days), in contrast, provided the kind of defensive growth profile that tends to appeal in late‑cycle debates, as investors looked to global scale, brand strength and pricing power to navigate any potential slowdown in discretionary spending.

Among more traditional cyclicals, Rio Tinto (RIO, $73.06, +1.54% over the last 5-days) served as a barometer for global industrial and commodity demand, with its fortunes tied to the trajectory of metals pricing and Chinese activity, while Nokia’s (NOK, $6.07, -.16% over the last 5-days) standing in the 5G and networking ecosystem left it sensitive to capex trends and competition in carrier and enterprise spending. Together, these names helped illustrate the market’s quiet rotation debates: growth at any price versus quality, defensiveness versus leverage to a potential global re‑acceleration.

Smaller names, speculative corners and IPOs

Newer or more speculative names such as OKLO ($104.67, +14.54% over the last 5-days) and Opendoor (OPEN, $7.15, -7.14% over the last 5-days) continued to trade as barometers of risk appetite in the higher‑beta fringes of the market, where moves are amplified by sentiment toward early‑stage technologies, housing activity, and the availability of capital. These stocks remained more sensitive to macro headlines and rate expectations than to index‑level calm, underscoring how the “AI and innovation” trade is increasingly stratified between established platforms and aspirational disruptors.

In the primary market, the U.S. IPO calendar stayed active but hardly euphoric: several SPACs and smaller offerings made their way to the screens, including a special‑purpose vehicle such as Activate Energy Acquisition Corp. on Nasdaq and additional listings tracked by IPO services, while larger headline deals remained mostly in the “watch this space” category. December thus began with a tone best described as selective rather than speculative, as issuers and bankers tried to thread the needle between favorable valuations and investors’ lingering memory of prior boom‑and‑bust cycles.

M&A, Netflix and Warner Bros.

The corporate‑action story of the week belonged decisively to Hollywood, where Netflix (NFLX, $100.24, -6.82% over the last 5-days) agreed to acquire Warner Bros.’ (WBD, $26.06, +6.28% over the last -5days) storied studio and streaming businesses — including HBO and HBO Max — in a transaction valued at roughly the low‑to‑mid‑$70‑billion range, plus assumed debt, instantly redrawing the entertainment map. Boards on both sides backed the deal, which is expected to close after a planned separation of Warner Bros. Discovery’s global networks business and remains subject to regulatory and shareholder approvals that will test policymakers’ appetite for further media consolidation.

Investors spent the back half of the week digesting what such a combination could mean for content costs, competitive dynamics and bargaining power with talent and distributors, as the transaction promised to merge an unmatched library of franchises with the world’s dominant subscription‑streaming platform. The deal also provided a timely reminder that even in a world obsessed with AI chips and cloud capacity, old‑fashioned scale in storytelling still commands a premium — at least when someone is willing to write a multibillion‑dollar check for it.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4564, +15.84% over the last 5-days), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, today (Nov. 17) announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.28, +1.13% over the last 5-days), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.3771), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.28) and M2i Global, Inc. (MTWO, $.10, +4.71% over the last 5-days), a company specializing in the development and execution of a complete global value supply chain for critical minerals, announced on Nov. 19 that Nimy Resources (“Nimy”) and M2i will collaborate with the aim of forming commercially binding contract terms for the respective sale and purchase of gallium production. They also announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.25) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have e96xhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $30.25, +1.30% over the last 5-days) reported (Nov. 17) results for the three months ended September 30, 2025. John V. Winfield, Chairman and Chief Executive Officer, said: “We continue to observe signs of stabilization and recovery across the San Francisco hospitality market, including improving convention calendars, tourism indicators, and business travel activity. On the investment side, our marketable securities activity remained modest with a small net gain, consistent with our emphasis on liquidity and risk discipline.”

Nokia (NOK, $6.07) is promising investors a sleeker, AI‑age version of itself by 2028, aiming to lift profits by as much as 60% while quietly admitting that the road there runs through a restructuring zone. Nokia today announced it has been selected by KPN, a Dutch telecommunications company, to help transform the Netherlands’ core digital infrastructure through the deployment of an 800G-capable IP and optical network. This nationwide initiative, known as FabriQ, forms the ‘digital aorta’ for all fixed and mobile services delivered by KPN to millions of consumer, business and wholesale users across a range of enterprise sectors, supporting increased speed, greater resilience and supporting KPN’s focus on reduced energy use. KPN is the leading telecom provider in the Netherlands, offering mobile, fixed-line, IT and wholesale services. The company has been rapidly expanding its fiber-optic network, aiming to make high-speed broadband widely available across the Netherlands.

Opendoor Technologies Inc. (OPEN, $7.15) a digital red estate disruptor, jumped higher once again as the belief that interest rates would be cut in December rose significantly.

DoubleVerify Holdings Inc. (DV) closed at $11.03, +4.65% over the last 5-days. DoubleVerify Holdings is a software company that helps advertisers verify and improve the quality and performance of their digital ads across the web, apps, social platforms, and connected TV. DoubleVerify provides a digital media measurement and analytics platform that checks whether ads are viewable, shown to real people (not bots), served in brand‑safe environments, and delivered in the right geography. Its tools give advertisers independent, third‑party data so they can reduce ad fraud, avoid unsafe content, and get better return on their digital ad spend. DoubleVerify primarily earns revenue by charging advertisers, agencies, and platforms based on the volume of media it measures (such as impressions or transactions). Its technology is integrated with major ad platforms and programmatic exchanges, and is used globally by brands, marketplaces, and publishers to monitor and optimize campaigns.

AI Titans, Fed Doubts and a +$70 Billion Hollywood Plot Twist: This Week in Markets – Dec. 5, 2025 -( $DV $EPRX $INTG $META $MODD $MTWO $NVDA $OKLO $ORCL $PLTR $TSLA $TSM $WBD Rise!)

Indexes and macro tone

Rates, yields, Fed and Washington

Commodities and crypto

Big tech, pharma and chip leaders

AI, software and data names

Autos, industrials, consumer and materials

Smaller names, speculative corners and IPOs

M&A, Netflix and Warner Bros.

VP Watchlist Updates

Sources

You May Also Like

Swiftonomics: How Taylor Swift’s Eras Tour Became a $10 Billion Economic Powerhouse

Japanese Pharmaceutical Giant Takeda Bets $11.4 Billion on China’s Innovent to Fuel Next-Gen Cancer Drug Pipeline – ( $TAK $IBB $XBI )

Your Guide To Staying Informed In The Markets